SWIFTPHARMA A REVOLUTIONARY STARTUP PROJECT TO SAVE MILLIONS OF HUMAN LIVES

SWIFTPHARMA A REVOLUTIONARY STARTUP PROJECT TO SAVE MILLIONS OF HUMAN LIVES

 

At Diplomatic World we strongly value the importance of health diplomacy. Diplomatic World would therefore like to inform its readers about SWIFTPHARMA. SWIFTPHARMA is a startup project that can save millions of human lives. If you want to prospect opportunities in this project[1], you can directly contact the project’s general advisor on Philippe.Billiet@billiet-co.be.

 

WHAT IS THE MAIN SOLUTION THAT CAN BE OFFERED THROUGH SWIFTPHARMA?

This deep tech project mainly aims at resolving bottlenecks for the fast follower production of vaccines. Currently, the production methodology of vaccines is either egg based or cell based. If egg based, 3 eggs are needed to produce 1 vaccine and the production method, from strain to vaccine, requires about 6 months. If cell based, the production method, from strain to vaccine, still requires about 4 months.

SWIFTPHARMA offers a much more efficient production methodology for vaccines. Its plant-based production methodology allows for 1 plant to produce 50 vaccines. Moreover, the production method from strain to vaccine requires only about 4 weeks.

SWIFTPHARMA’s plant-based production methodology also offers significant CapEx and OpEx reduction, swift scalability, and removal of capacity limitations, compared to the traditional production methods of vaccines.

The project (currently in start-up) should relatively soon enable to produce billions of vaccines in short delay, at fair pricing levels.

 

WHICH PROBLEMS IN RELATION TO VACCINE PRODUCTION CAN BE IMMEDIATELY RESOLVED THROUGH SWIFTPHARMA?

SWIFTPHARMA’s solution satisfies all the following needs regarding for the production of vaccines:

  • Fast: From gene sequence to purified antigen in only 35 days, avoiding lengthy clone selection and MCB establishment by “transfecting at scale”.
  • Scalable: Linearly scalable and therefore avoiding time-consuming scale-up challenges.
  • High quality: Production of consistent therapeutics with accessible, flexible glycosylation controls that are well-accepted by global regulatory bodies.
  • Cost-efficient: Lower facility CapEx and OpEx compared to traditional technologies. No costly, labour-intensive, cell-line development.
  • Sustainable: A truly “green” manufacturing method. No plastic waste when plants are used as “single-use” bioreactors.
  • Safe: Mammalian viruses cannot grow in plants, which minimizes contamination risks. No animal-derived components are used at any point.
  • Reliable: SWIFTPHARMA’s production methodology can be used for the production of any kind of vaccine against viruses.

 

WHAT OTHER SOLUTIONS MAY SWIFTPHARMA BRING FOR THE FUTURE?

SWIFTPHARMA aims at developing next-gen mucosal universal vaccines. Through collaborations, SWIFTPHARMA helps to develop new generation universal vaccines for Influenza and Corona viruses.  The focus points are (I) vaccines for universal protection against future Corona – or Influenza viruses, and (II) a mucosal delivery system for immunization via nasal spray.

SWIFTPHARMA also aims at improving production processes through automation and crop improvement. Through collaborations, itwill scale-up production process to industrial scale by growing N. benthamiana plants vertically and hydroponically in a highly constrained and controlled environment.  These efforts enable to develop the first plant-based vaccine manufacturing facility based in the EU.

Collaborations will also enable SWIFTPHARMA to generate further improved N. benthamiana plants that produce even more biomass in the same growth curve, leading to using less plants per kilo of biomass.

 

WHICH MARKETS CAN BE SERVED THROUGH THIS PROJECT?

The target market will in the first place include all entities that are in need for a much more efficient production method for vaccines, wanting to better meet the consumers’ interests in reliable and rapid access to safe vaccines.

Besides the production of vaccines, SWIFTPHARMA’s solution can also serve the following production markets:

  1. Antibodies (Therapeutic and/or high throughput research grade monoclonal or polyclonal);
  2. Enzymes (Enzyme replacement therapy, protease inhibitors, universal blood enzymes);
  3. Cytokines (Blood coagulation factors, growth factors, interleukins);
  4. Maturogens (Scaffolds, maturogens and materials for 3D bioprinting and biofabrication);
  5. Proteins for cosmetic applications (growth factors, enzymes)

 

In addition, the breakthrough innovative solution of SWIFTPHARMA has also been picked up in the field of cancer prevention, where several leading oncologists and researchers consider SWIFTPHARMA as a suitable partner for production.

 

WHY IS THIS PROJECT SO REVOLUTIONARY?

SWIFTPHARMA’s production facility must help to save millions of human lives worldwide and help authorities to become able to swiftly address current and future viral pandemic scenarios.

The project includes the construction and development of the first state-of-the art plant-based lab-factory in the EU (Belgium). It is the first time that plants would be used as biofactories in the EU for large volume vaccine production. SWIFTPHARMA’s patented production process is based upon 2 existing production methods outside the EU that have been significantly improved by introducing high level of automation, improving plant biomass/growth curve ratios and improving expression vectors.

The newly introduced production process offers major economic advantages by creating synergy, decreasing CAPEX, increasing capacity, etc. The future production cost for vaccines can therefore decrease tremendously.

Moreover, SWIFTPHARMA’s plant-based methodology leaves no ecologic footprint and contributes to environmental friendliness and climate-interests.

In Addition, since mammalian viruses cannot grow in plants, this project helps to erase contamination risks in vaccine production. The lab-factory should therefore not include risks for new contaminations to humans.

Consequently, this project should enable safe mass production of future vaccines and allow all users to swiftly obtain vaccination at a fair cost.

 

WHY WILL THIS STARTUP PROJECT LIKELY BE SUCCESFUL?

The current pandemic scenario results in a broad awareness for the need to become able to swiftly produce vaccines, to rapidly deploy vaccines also in locations that are difficult to reach, and at fair price levels.

Besides the production of vaccines, the production methods offered by SWIFTPHARMA can also serve the following production markets: Antibodies; Enzymes; Cytokines; Maturogens; and Proteins for cosmetics industry.

SWIFTPHARMA’s breakthrough innovative solution has also been picked up in the field of cancer prevention, where leading oncologists and researchers consider SWIFTPHARMA as suitable partner for production.

Moreover, the solution offered by SWIFTPHARMA is based on over 10 years of prior research and is IP protected.

 

WHO SHOULD CARE ABOUT THIS PROJECT?

The following actors should with great interest look into this startup project:

  • All entities that are in need for a much more efficient and safe production method for vaccines, wanting to better meet the consumers’ interests in reliable and rapid access to safe vaccines.
  • Market operators in the field of Antibodies (Therapeutic and/or high throughput research grade monoclonal or polyclonal);
  • Market operators in the field of Enzymes (Enzyme replacement therapy, protease inhibitors, universal blood enzymes);
  • Market operators in the field of Cytokines (Blood coagulation factors, growth factors, interleukins)
  • Market operators in the field of Maturogens (Scaffolds, maturogens and materials for 3D bioprinting and biofabrication)
  • Market operators in the field of Cosmetics
  • Market operators in the field of Agro science

 

WHAT ARE THE MAIN SHORT-TERM TARGETS ON SWIFTPHARMA’S INTENDED PROJECT TIMELINE?

The first EU plant-based lab-factory facility should become fully operational by end 2022.

By end of 2023, the facility must be performing CDMO services for each of the following industries: Vaccines, Cosmetics, Agro science, Enzymes, Antibodies.

By the end of 2024, the lab-factory facility must have completed the following phases to develop its own next-gen vaccine technology:  Proof of Concept, pre-clinical phase 1, phase 2 (A&B)

By the end of 2026, the lab-factory facility must bring to the market a universal vaccine technology for mucosal immunization that protects against all variants of a corona- or influenza virus, or at least offer a broader protection against a wide variety thereof.

[1]E.g. as a business partner or as a mission that wants to facilitate development through economic diplomacy & health diplomacy.